Review

anti htlr4 igg (InvivoGen)

Name: anti htlr4 igg
Brand: InvivoGen
Rating: 93 (36 reviews)

InvivoGen is a verified supplier

InvivoGen manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

InvivoGen anti htlr4 igg
Anti Htlr4 Igg, supplied by InvivoGen, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti htlr4 igg/product/InvivoGen
Average 93 stars, based on 1 article reviews

anti htlr4 igg - by Bioz Stars, 2025-04

93/100 stars

Images

Image Search Results

Full-length SARS-CoV-2 spike stimulates IL-1β secretion from human mast cells via TLR4 signaling. LADR mast cells (2.5 × 10 5 cells) were pretreated with anti-TLR2 Ab (2 μg/mL), anti-TLR4 Ab (2 μg/mL), or anti-ACE2 Ab (2 μg/mL) for 1 h and then stimulated with recombinant full-length SARS-CoV-2 S (10 ng/mL) for 1 h and 24 h, respectively. Secretion of chymase ( A ), tryptase ( B ) , and IL-1β ( C ) was determined by specific ELISAs. All conditions were performed in triplicate for each dataset and repeated 3 times ( n = 3). The horizontal brackets indicate the corresponding levels of significance when present ( p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), and p < 0.0001 (****)).

Journal: International Journal of Molecular Sciences

Article Title: Recombinant SARS-CoV-2 Spike Protein Stimulates Secretion of Chymase, Tryptase, and IL-1β from Human Mast Cells, Augmented by IL-33

doi: 10.3390/ijms24119487

Figure Lengend Snippet: Full-length SARS-CoV-2 spike stimulates IL-1β secretion from human mast cells via TLR4 signaling. LADR mast cells (2.5 × 10 5 cells) were pretreated with anti-TLR2 Ab (2 μg/mL), anti-TLR4 Ab (2 μg/mL), or anti-ACE2 Ab (2 μg/mL) for 1 h and then stimulated with recombinant full-length SARS-CoV-2 S (10 ng/mL) for 1 h and 24 h, respectively. Secretion of chymase ( A ), tryptase ( B ) , and IL-1β ( C ) was determined by specific ELISAs. All conditions were performed in triplicate for each dataset and repeated 3 times ( n = 3). The horizontal brackets indicate the corresponding levels of significance when present ( p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), and p < 0.0001 (****)).

Article Snippet: LADR Mast Cell Treatments : LADR mast cells were stimulated with recombinant full-length SARS-CoV-2 S (1–10 ng/mL; ab281471, Abcam, Cambridge, UK) or RBD (1–10 ng/mL; ab273065, Abcam, Cambridge, UK), and/or preincubated with the following: (1) anti-TLR2 antibody (2 μg/mL, 1 h; maba2-htlr2, InvivoGen, San Diego, CA, USA), (2) anti-TLR4 antibody (2 μg/mL, 1 h; mabg-htlr4, InvivoGen, San Diego, CA, USA) and (3) anti-ACE2 antibody (2 μg/mL, 1 h; ab108209, InvivoGen, San Diego, CA, USA).

Techniques: Recombinant

AZ617 is a human-specific, TLR4-dependent agonist that activates NFκB. A. Stimulation of human PBMCs, but not mouse splenocytes, with AZ617 for 24 hours effected a concentration-dependent release of NFκB-related cytokines IFNγ, IL-1β, TNFα, and IL-6. Representative graphs generated from 4 independent experiments. B. AZ617 activity was reduced when human PBMCs were pre-treated with an anti-human TLR4 blocking reagent for one hour prior to stimulation. Representative graphs derived from 2 independent experiments. Unpaired t-test **p#x003C;0.01, ***p#x003C;0.001. Error bars represent standard error of the mean (SEM).

Journal: Journal of Biological Methods

Article Title: Utilizing a human TLR selective ligand in a humanized immune system mouse model to investigate human TLR4 signaling

doi: 10.14440/jbm.2023.408

Figure Lengend Snippet: AZ617 is a human-specific, TLR4-dependent agonist that activates NFκB. A. Stimulation of human PBMCs, but not mouse splenocytes, with AZ617 for 24 hours effected a concentration-dependent release of NFκB-related cytokines IFNγ, IL-1β, TNFα, and IL-6. Representative graphs generated from 4 independent experiments. B. AZ617 activity was reduced when human PBMCs were pre-treated with an anti-human TLR4 blocking reagent for one hour prior to stimulation. Representative graphs derived from 2 independent experiments. Unpaired t-test **p#x003C;0.01, ***p#x003C;0.001. Error bars represent standard error of the mean (SEM).

Article Snippet: For TLR4-dependency studies, human PBMCs were pre-incubated with 12.5 μg/mL anti-human TLR4 blocking antibody (Invivogen, mabg-htlr4) for 1 hour at 37ºC prior to stimulation with 50 ng/mL AZ617 for an additional 24 hours.

Techniques: Concentration Assay, Generated, Activity Assay, Blocking Assay, Derivative Assay

Functionality of KISIMA vaccine. ( A ) Scheme of ATP128 constructs. ATP128 full length (FL) is comprised of a Cell Penetrating Peptide (CPP) at the N-terminus, a Multiantigenic domain (Mad), and a TLR agonist at the C-terminus (Anaxa). ( B ) THP-1 Dual cells were incubated with increasing concentrations of ATP128 vaccine constructs. After 18 h, supernatant was recovered and either SEAP activity was measured by QUANTI-Blue assay (left panel), or Luciferase activity was measured by QUANTI-Luc assay (right panel). The EC50s of the different constructs were calculated from the obtained dose-response curve using the GraphPad Prism software. Experiments shown here represent the average of % of activation of 3 biological replicates. ( C ) THP-1 Dual cells were incubated with 300 nM ATP128 in presence or not of blocking antibodies anti-TLR. After 18 h, cell supernatants were recovered, assessed, and represented as described above. The values reported here are the mean of 4 biological replicates. Values were compared using a one-way ANOVA test to the untreated sample (positive control—no blocking antibody). ( D ) THP-1 Dual cells wild-type (WT) or knocked-out (KO) for specific TLR were stimulated with 300 nM ATP128. After 18 h, the cell supernatants were recovered, assessed, and represented as described above. The values reported here are a mean of 3 biological replicates. Values were compared via one-way ANOVA test to the WT sample. ( E ) THP-1 Dual cells were incubated with 300 nM ATP128 in presence or not of the TLR4 inhibitor CLI-095. After 18 h, the cell supernatants were recovered, assessed, and represented as described above. The values reported here are a mean of 4 biological replicates. Values were compared via one-way ANOVA test to the untreated sample (positive control). ( F ) THP-1 Dual WT, and TLR2 KO and TLR4 KO cells were incubated with 300 nM ATP128 in presence or not of antibodies anti-TLR and CLI-095. After 18 h, the cell supernatants were recovered, assessed, and represented as described above. The values reported here are a mean of 3 biological replicates. Values were compared via a one-way ANOVA test to the untreated sample in WT cells. **** p -value < 0.0001, *** p -value < 0.001, ** p -value < 0.01, * p -value < 0.1. ns: no significance.

Journal: Cancers

Article Title: ATP128 Clinical Therapeutic Cancer Vaccine Activates NF-κB and IRF3 Pathways through TLR4 and TLR2 in Human Monocytes and Dendritic Cells

doi: 10.3390/cancers14205134

Figure Lengend Snippet: Functionality of KISIMA vaccine. ( A ) Scheme of ATP128 constructs. ATP128 full length (FL) is comprised of a Cell Penetrating Peptide (CPP) at the N-terminus, a Multiantigenic domain (Mad), and a TLR agonist at the C-terminus (Anaxa). ( B ) THP-1 Dual cells were incubated with increasing concentrations of ATP128 vaccine constructs. After 18 h, supernatant was recovered and either SEAP activity was measured by QUANTI-Blue assay (left panel), or Luciferase activity was measured by QUANTI-Luc assay (right panel). The EC50s of the different constructs were calculated from the obtained dose-response curve using the GraphPad Prism software. Experiments shown here represent the average of % of activation of 3 biological replicates. ( C ) THP-1 Dual cells were incubated with 300 nM ATP128 in presence or not of blocking antibodies anti-TLR. After 18 h, cell supernatants were recovered, assessed, and represented as described above. The values reported here are the mean of 4 biological replicates. Values were compared using a one-way ANOVA test to the untreated sample (positive control—no blocking antibody). ( D ) THP-1 Dual cells wild-type (WT) or knocked-out (KO) for specific TLR were stimulated with 300 nM ATP128. After 18 h, the cell supernatants were recovered, assessed, and represented as described above. The values reported here are a mean of 3 biological replicates. Values were compared via one-way ANOVA test to the WT sample. ( E ) THP-1 Dual cells were incubated with 300 nM ATP128 in presence or not of the TLR4 inhibitor CLI-095. After 18 h, the cell supernatants were recovered, assessed, and represented as described above. The values reported here are a mean of 4 biological replicates. Values were compared via one-way ANOVA test to the untreated sample (positive control). ( F ) THP-1 Dual WT, and TLR2 KO and TLR4 KO cells were incubated with 300 nM ATP128 in presence or not of antibodies anti-TLR and CLI-095. After 18 h, the cell supernatants were recovered, assessed, and represented as described above. The values reported here are a mean of 3 biological replicates. Values were compared via a one-way ANOVA test to the untreated sample in WT cells. **** p -value < 0.0001, *** p -value < 0.001, ** p -value < 0.01, * p -value < 0.1. ns: no significance.

Article Snippet: For THP-1 activation assays: anti-mouse TLR2 (mab2-mtlr2) and anti-human TLR4 (mabg-htlr4) antibodies were purchased from InvivoGen.

Techniques: Construct, Incubation, Activity Assay, Luciferase, Software, Activation Assay, Blocking Assay, Positive Control

ATP128 engages mostly TLR4 for human moDC activation in an ex vivo system. ( A , B ) Human moDC were pre-treated with anti-TLR2, anti-TLR4 or CLI-095 for 1 h, then stimulated for 24 h with 300 nM ATP128. Cells were collected after stimulation, and surface costimulatory molecules ( A ) and HLA class I and II molecules ( B ) were analyzed through flow cytometry. Each shape is representative of a different buffy coat. Histograms of one representative buffy coat are shown below. Values were compared via one-way ANOVA test to the sample stimulated with ATP128 FL. **** p -value < 0.0001, * p -value < 0.05.

Journal: Cancers

Article Title: ATP128 Clinical Therapeutic Cancer Vaccine Activates NF-κB and IRF3 Pathways through TLR4 and TLR2 in Human Monocytes and Dendritic Cells

doi: 10.3390/cancers14205134

Figure Lengend Snippet: ATP128 engages mostly TLR4 for human moDC activation in an ex vivo system. ( A , B ) Human moDC were pre-treated with anti-TLR2, anti-TLR4 or CLI-095 for 1 h, then stimulated for 24 h with 300 nM ATP128. Cells were collected after stimulation, and surface costimulatory molecules ( A ) and HLA class I and II molecules ( B ) were analyzed through flow cytometry. Each shape is representative of a different buffy coat. Histograms of one representative buffy coat are shown below. Values were compared via one-way ANOVA test to the sample stimulated with ATP128 FL. **** p -value < 0.0001, * p -value < 0.05.

Article Snippet: For THP-1 activation assays: anti-mouse TLR2 (mab2-mtlr2) and anti-human TLR4 (mabg-htlr4) antibodies were purchased from InvivoGen.

Techniques: Activation Assay, Ex Vivo, Flow Cytometry

Journal: Cancers

Article Title: ATP128 Clinical Therapeutic Cancer Vaccine Activates NF-κB and IRF3 Pathways through TLR4 and TLR2 in Human Monocytes and Dendritic Cells

doi: 10.3390/cancers14205134

Figure Lengend Snippet: ATP128 activates human moDCs in a profile similar to the TLR4 agonist, MPLA, in an ex vivo system. ( A , B ) Human moDC were incubated for 24 h with 300 nM ATP128 or 600 nM MPLA or 1 ng/mL FSL-1. Cells were collected after stimulation and surface costimulatory molecules ( A ) and HLA class I and class II molecules ( B ) were analyzed through flow cytometry. Each shape is representative of a different buffy coat. Histograms of one representative buffy coat are shown below. Values were compared via one-way ANOVA test to the sample stimulated with ATP128 FL., *** p -value < 0.001, ** p -value < 0.01, * p -value < 0.05.

Article Snippet: For THP-1 activation assays: anti-mouse TLR2 (mab2-mtlr2) and anti-human TLR4 (mabg-htlr4) antibodies were purchased from InvivoGen.

Techniques: Ex Vivo, Incubation, Flow Cytometry

ATP128 induces cytokines release upon activation of both the NF-κB and IRF3 pathways. ( A ) Human moDC were pre-treated with anti-TLR2, anti-TLR4, or CLI-095 for 1 h, then stimulated for 6 h or 24 h (for IL-12) with 300 nM ATP128. Cell supernatants were collected to assess the signature of cytokines secretion upon ATP128 stimulation through a multiplex cytokine assay. The values in the graphs represent the fold increase of the stimulated samples to the medium. Each shape is representative of a different buffy coat. Represented are the cytokines that are mainly induced upon stimulation. Values were compared via one-way ANOVA test to the sample stimulated with ATP128 FL. ( B ) Human moDC were incubated for 6 h or 24 h (for IL-12) with 300 nM ATP128 or 600 nM MPLA or 1 ng/mL FSL-1. Cell supernatants were collected to assess the signature of cytokines secretion through a multiplex cytokine assay (same as above). The values in the graphs represent the fold increase of the stimulated samples to the medium. Each shape is representative of a different buffy coat. Represented are the cytokines that are mainly induced upon stimulation. Values were compared via one-way Anova test to the sample treated with the buffer (negative control *** p -value < 0.001, ** p -value < 0.01, * p -value < 0.05.

Journal: Cancers

Article Title: ATP128 Clinical Therapeutic Cancer Vaccine Activates NF-κB and IRF3 Pathways through TLR4 and TLR2 in Human Monocytes and Dendritic Cells

doi: 10.3390/cancers14205134

Figure Lengend Snippet: ATP128 induces cytokines release upon activation of both the NF-κB and IRF3 pathways. ( A ) Human moDC were pre-treated with anti-TLR2, anti-TLR4, or CLI-095 for 1 h, then stimulated for 6 h or 24 h (for IL-12) with 300 nM ATP128. Cell supernatants were collected to assess the signature of cytokines secretion upon ATP128 stimulation through a multiplex cytokine assay. The values in the graphs represent the fold increase of the stimulated samples to the medium. Each shape is representative of a different buffy coat. Represented are the cytokines that are mainly induced upon stimulation. Values were compared via one-way ANOVA test to the sample stimulated with ATP128 FL. ( B ) Human moDC were incubated for 6 h or 24 h (for IL-12) with 300 nM ATP128 or 600 nM MPLA or 1 ng/mL FSL-1. Cell supernatants were collected to assess the signature of cytokines secretion through a multiplex cytokine assay (same as above). The values in the graphs represent the fold increase of the stimulated samples to the medium. Each shape is representative of a different buffy coat. Represented are the cytokines that are mainly induced upon stimulation. Values were compared via one-way Anova test to the sample treated with the buffer (negative control *** p -value < 0.001, ** p -value < 0.01, * p -value < 0.05.

Article Snippet: For THP-1 activation assays: anti-mouse TLR2 (mab2-mtlr2) and anti-human TLR4 (mabg-htlr4) antibodies were purchased from InvivoGen.

Techniques: Activation Assay, Multiplex Assay, Cytokine Assay, Incubation, Negative Control

Both CPP and Anaxa are essential for human moDC activation. ( A ) Human moDC were pre-treated with a combination of anti-TLR2 and anti-TLR4 for 1 h, then stimulated for 24 h with 300 nM ATP128 FL, ATP128 w / o CPP, or ATP128 w / o Anaxa. Cells were collected after stimulation and surface costimulatory molecules ( A ) and HLA class I and class II molecules ( B ) were analyzed through flow cytometry. Each shape is representative of a different buffy coat. Histograms of one representative buffy coat are shown below. Values were compared via one-way ANOVA test to the sample stimulated with ATP128 FL. **** p -value < 0.0001, *** p -value < 0.001, ** p -value < 0.01, * p -value < 0.05.

Journal: Cancers

Article Title: ATP128 Clinical Therapeutic Cancer Vaccine Activates NF-κB and IRF3 Pathways through TLR4 and TLR2 in Human Monocytes and Dendritic Cells

doi: 10.3390/cancers14205134

Figure Lengend Snippet: Both CPP and Anaxa are essential for human moDC activation. ( A ) Human moDC were pre-treated with a combination of anti-TLR2 and anti-TLR4 for 1 h, then stimulated for 24 h with 300 nM ATP128 FL, ATP128 w / o CPP, or ATP128 w / o Anaxa. Cells were collected after stimulation and surface costimulatory molecules ( A ) and HLA class I and class II molecules ( B ) were analyzed through flow cytometry. Each shape is representative of a different buffy coat. Histograms of one representative buffy coat are shown below. Values were compared via one-way ANOVA test to the sample stimulated with ATP128 FL. **** p -value < 0.0001, *** p -value < 0.001, ** p -value < 0.01, * p -value < 0.05.

Article Snippet: For THP-1 activation assays: anti-mouse TLR2 (mab2-mtlr2) and anti-human TLR4 (mabg-htlr4) antibodies were purchased from InvivoGen.

Techniques: Activation Assay, Flow Cytometry

The absence of the CPP and Anaxa domain greatly affects the secretion of pro-inflammatory cytokines and type I IFN. Human moDC were treated with a combination of anti-TLR2 and anti-TLR4 and incubated for 6 h with 300 nM ATP128 FL, w / o CPP, or w / o Anaxa. Cell supernatants were collected to assess the signature of cytokines secretion upon ATP128 stimulation through a multiplex cytokine assay. The values in the graphs represent the fold increase of the stimulated samples to the medium. Each shape is representative of a different buffy coat. Represented are the cytokines that are mainly induced upon stimulation. Values were compared via one-way ANOVA test to the sample stimulated with ATP128 FL*** p -value < 0.001, ** p -value < 0.01, * p -value < 0.05.

Journal: Cancers

Article Title: ATP128 Clinical Therapeutic Cancer Vaccine Activates NF-κB and IRF3 Pathways through TLR4 and TLR2 in Human Monocytes and Dendritic Cells

doi: 10.3390/cancers14205134

Figure Lengend Snippet: The absence of the CPP and Anaxa domain greatly affects the secretion of pro-inflammatory cytokines and type I IFN. Human moDC were treated with a combination of anti-TLR2 and anti-TLR4 and incubated for 6 h with 300 nM ATP128 FL, w / o CPP, or w / o Anaxa. Cell supernatants were collected to assess the signature of cytokines secretion upon ATP128 stimulation through a multiplex cytokine assay. The values in the graphs represent the fold increase of the stimulated samples to the medium. Each shape is representative of a different buffy coat. Represented are the cytokines that are mainly induced upon stimulation. Values were compared via one-way ANOVA test to the sample stimulated with ATP128 FL*** p -value < 0.001, ** p -value < 0.01, * p -value < 0.05.

Article Snippet: For THP-1 activation assays: anti-mouse TLR2 (mab2-mtlr2) and anti-human TLR4 (mabg-htlr4) antibodies were purchased from InvivoGen.

Techniques: Incubation, Multiplex Assay, Cytokine Assay

HEK-Blue™ hTLR2 and HEK-Blue™ hTLR4 cells were treated with different concentrations (100 ng/ml, 200 ng/ml, 400 ng/ml, 800 ng/ml, 1.6 μg/ml, 3.2 μg/ml and 6.4 μg/ml) of proteins Rv2659c ( A and C ) and Rv1738 ( B and D ) for 16 hours before measuring SEAP production by microplate reader. 1 x PBS and Pro K-digested protein were used as the negative controls, while FSL-1 (100 ng/ml) and LPS (1 μg/ml) were served as the positive controls for TLR2 and TLR4, respectively. Data are represented as mean ± SD of triplicate experiments (Each was duplicated). One-way ANOVA with Dunnett’s multiple comparison test was used for statistical analysis. p values are represented with asterisk symbols (*p < 0.05 **p < 0.01, ***p < 0.001 and ****p < 0.0001).

Journal: PLoS ONE

Article Title: Toll-like receptor-mediated innate immune responses by recognition of the recombinant dormancy-associated Mycobacterium tuberculosis proteins Rv2659c and Rv1738

doi: 10.1371/journal.pone.0273517

Figure Lengend Snippet: HEK-Blue™ hTLR2 and HEK-Blue™ hTLR4 cells were treated with different concentrations (100 ng/ml, 200 ng/ml, 400 ng/ml, 800 ng/ml, 1.6 μg/ml, 3.2 μg/ml and 6.4 μg/ml) of proteins Rv2659c ( A and C ) and Rv1738 ( B and D ) for 16 hours before measuring SEAP production by microplate reader. 1 x PBS and Pro K-digested protein were used as the negative controls, while FSL-1 (100 ng/ml) and LPS (1 μg/ml) were served as the positive controls for TLR2 and TLR4, respectively. Data are represented as mean ± SD of triplicate experiments (Each was duplicated). One-way ANOVA with Dunnett’s multiple comparison test was used for statistical analysis. p values are represented with asterisk symbols (*p < 0.05 **p < 0.01, ***p < 0.001 and ****p < 0.0001).

Article Snippet: The hPBMCs were plated in 96-well cell culture plates (Corning, NY, USA); 5 μg/ml (final concentration) of anti-hTLR2 antibody (PAb-hTLR2; Invivogen, USA) and anti-hTLR4 antibody (PAb-hTLR4; Invivogen, USA) were added.

Techniques: Comparison

(A) Cytokine production from hTLR2 blocking group. (B) Cytokine production from hTLR4 blocking group. The ligand-binding pockets of hTLR2 and hTLR4 in human PBMCs were blocked with 5 μg/ml of anti-hTLR2 and anti-hTLR4 antibodies, respectively, for 1 hour. Protein Rv2659c (6.4 μg/ml) was then added and incubated for the next 24 hours. For the blockings of untreated cells, FSL-1 (100 ng/ml) and LPS (1 μg/ml) served as systemic controls. IL-1β, IL-6, IL-8, IL-10 and TNF-α in the culture supernatants were quantitated by CBA assay. Data were evaluated by flow cytometry, analyzed by FCAP array software and represented as mean ± SEM of 3 individual subjects (each was done in duplicate). One-way ANOVA with Sidak’s post hoc test was used for statistical analysis. p values are represented with asterisk symbols (*p < 0.05 **p < 0.01, ***p < 0.001 and ****p < 0.0001).

Journal: PLoS ONE

Article Title: Toll-like receptor-mediated innate immune responses by recognition of the recombinant dormancy-associated Mycobacterium tuberculosis proteins Rv2659c and Rv1738

doi: 10.1371/journal.pone.0273517

Figure Lengend Snippet: (A) Cytokine production from hTLR2 blocking group. (B) Cytokine production from hTLR4 blocking group. The ligand-binding pockets of hTLR2 and hTLR4 in human PBMCs were blocked with 5 μg/ml of anti-hTLR2 and anti-hTLR4 antibodies, respectively, for 1 hour. Protein Rv2659c (6.4 μg/ml) was then added and incubated for the next 24 hours. For the blockings of untreated cells, FSL-1 (100 ng/ml) and LPS (1 μg/ml) served as systemic controls. IL-1β, IL-6, IL-8, IL-10 and TNF-α in the culture supernatants were quantitated by CBA assay. Data were evaluated by flow cytometry, analyzed by FCAP array software and represented as mean ± SEM of 3 individual subjects (each was done in duplicate). One-way ANOVA with Sidak’s post hoc test was used for statistical analysis. p values are represented with asterisk symbols (*p < 0.05 **p < 0.01, ***p < 0.001 and ****p < 0.0001).

Techniques: Blocking Assay, Ligand Binding Assay, Incubation, Flow Cytometry, FCAP Assay, Software

Journal: PLoS ONE

Article Title: Toll-like receptor-mediated innate immune responses by recognition of the recombinant dormancy-associated Mycobacterium tuberculosis proteins Rv2659c and Rv1738

doi: 10.1371/journal.pone.0273517

Figure Lengend Snippet: (A) Cytokine production from hTLR2 blocking group. (B) Cytokine production from hTLR4 blocking group. The ligand-binding pockets of hTLR2 and hTLR4 in human PBMCs were blocked with 5 μg/ml of anti-hTLR2 and anti-hTLR4 antibodies, respectively, for 1 hour. Recombinant protein Rv1738 (6.4 μg/ml) was subsequently added and incubated for the next 24 hours. Blockings of untreated cells, FSL-1 (100 ng/ml) and LPS (1 μg/ml) were applied as the systemic controls. A set of cytokines (IL-1β, IL-6, IL-8, IL-10 and TNF-α) in the culture supernatants was quantitated by CBA assay. Data were evaluated by flow cytometry, analyzed by FCAP array software and represented as mean ± SEM of 3 individual subjects (each experiment was done in duplicate). One-way ANOVA with Sidak’s post hoc test was used for statistical analysis. p values were represented with asterisk symbols (*p < 0.05 **p < 0.01, ***p < 0.001 and ****p < 0.0001).

Techniques: Blocking Assay, Ligand Binding Assay, Recombinant, Incubation, Flow Cytometry, FCAP Assay, Software

Review

Structured Review

Images

Similar Products

Image Search Results